-
Register
- User - $30
There are many algorithms available for NPs to utilize to support prescribing decisions. This presentation will use various case studies to determine the appropriate use of medication and improve the utilization of evidence-based guidelines.
Credits: 1.00 contact hours; 1.00 are pharmacology
Expiration Date: December 31st, 2024
$30
LEARNING OBJECTIVES
As a result of this activity, the learner will be able to:
- Utilize the Endocrine Society Guideline for prescribing for a patient with obesity.
- Apply the ADA Guideline for prescribing for a patient with diabetes.
- Employ the AHA/ACC guideline for prescribing for a patient with dyslipidemia.
CE INFORMATION
Obtain Your Credits
To earn credits for this activity, you must complete all course components in the following order: 1) complete a three-question pre-test; 2) watch the course presentation video; 3) complete the course evaluation; 4) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile dashboard transcript for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.00 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
DISCLOSURES
Faculty
Contributing faculty, Angela Golden, DNP, FNP-C, FAANP, have disclosed the following relevant financial relationships: Speaker's Bureau for Takeda and Salix; Speaker's Bureau and Advisory Board for Novo Nordisk; Consultant for Unjury.
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity.
Key:
Complete
Next
Failed
Available
Locked
